<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

 

Melanoma PDX Models 
A Champions Model Cohort

Advance your Melanoma drug development research using an extensive bank of meticulously curated Melanoma PDX models directly established from primary  patient tumors. 

 

 

Download the Model Cohort

 Clinically Relevant Models

Living & diverse bank of clinically relevant models that correlate with clinical outcomes

Pretreated PDX Models

Established from tumor biopsies from patients pretreated with latest generation therapies

Multi-omic Characterization

Clinical annotations coupled with molecular datasets and in vivo responses 

 

Advance your Melanoma Therapeutic Pipeline with Confidence 

Champions Oncology has established a large cohort of patient Melanoma PDX models, with 47* models available to scientists for melanoma research and drug development. These models are derived from patients with late-stage, metastatic, and heavily pretreated patients while retaining critical molecular features and alterations, making them therapeutically relevant.  (*Model numbers fluctuate as our dataset continuously evolves.)

Champions' leading Melanoma PDX Models cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history. 

  • Access to one of the largest  bank of Melanoma PDX models with clinically relevant molecular
    and pathological characteristics on the market. 
  • Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.
  • Includes models pretreated with advanced therapies like Vemurafenib, Carboplatin, Ipilimumab, and more.